Bristol-Myers Squibb (BMY)/Celgene (CELG) Merger Spread Continues to Narrow
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $49.30 +0.33%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
Revenue Growth %: +1.4%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
Revenue Growth %: +1.4%
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) and Celgene (NASDAQ: CELG) deal spread continues to narrow. Last 13.1% after being as high as 22.3%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU Antitrust Regulators Concerned About Impact of KKR, Telecom Italia Deal on Viability of Wholesale Market - Reuters
- Bristol-Myers Squibb (BMY) and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies
- Jana, in Letter, Urges Wolfspeed (WOLF) to Eye Sale, Other Strategic Alternatives - Reuters
Create E-mail Alert Related Categories
Mergers and Acquisitions, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
